The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density: A Prospective Interventional Two-stage Simon Design Phase II Study.
Latest Information Update: 25 Sep 2021
Price :
$35 *
At a glance
- Drugs Sintilimab (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 31 Jul 2021 New trial record
- 08 Jun 2021 Status changed from recruiting to completed as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology